Has Alexander Wei, MD received payments from drug or device companies?

Yes. Drug and device makers reported $11,832 in general payments to Alexander Wei, MD across 29 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Alexander Wei, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Alexander Wei, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Alexander Wei, MD

Medical Oncology · New York, NYNPI 1750814026

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (48.9%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Merck accounts for 60.4% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $7,971, 4.3 times the $1,874 reported in 2022.

$11,832in general payments, 2019–2025

Across 29 payments — averaging $408.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Merck$7K
Sanofi$2K
Telix Pharmaceuticals$982
F. Hoffmann-la Roche AG$849
Trisalus Life Sciences, Inc.$332
E.r. Squibb & Sons, L.L.C.$199
plus $465 from 5 others

$1,494,943in research payments, 2019–2025

Across 59 payments — averaging $25,338 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novartis$535K
Eli Lilly$374K
Trisalus Life Sciences, Inc.$247K
Regeneron$139K
E.r. Squibb & Sons, L.L.C.$76K
Genentech, Inc.$72K
plus $53K from 1 others

What the payments were for

Consulting fees$1,83015%
Speaking & faculty fees$5,79049%
Travel & lodging$2,27719%
Food & beverage$1,93516%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Merck	7	$7,149
Sanofi	2	$1,856
Telix Pharmaceuticals	8	$982
F. Hoffmann-la Roche AG	2	$849
Trisalus Life Sciences, Inc.	2	$332
E.r. Squibb & Sons, L.L.C.	2	$199
Seagen Inc.	1	$150
AstraZeneca	2	$137
Pfizer	1	$135
Johnson & Johnson	1	$26
Oxford Immunotec USA Inc	1	$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,832 in reported general payments places this provider in the 60th percentile of 498 medical oncology providers in New York.

See all medical oncology providers in New York →

Medicare billing

Part B allowed, 2024

$144,054

Medicare patients

172

Services billed

1,209

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Amlodipine Besylate	22	$142
Metoprolol Succinate	13	$87

Paid to pharmacies, not to this prescriber.

Other medical oncology in New York

Craig ThompsonNew York$4.8M
Andrew SeidmanNew York$1.3M
Joshua RichterNew York$971K
Edward GelmannNew York$944K
Ghassan Abou-AlfaNew York$825K
Miguel PeralesNew York$769K
Komal JhaveriNew York$642K
Joshua BrodyNew York$492K
Aiwu HeNew York$445K
Raajit RampalNew York$418K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →